全文获取类型
收费全文 | 1334270篇 |
免费 | 95862篇 |
国内免费 | 2904篇 |
专业分类
耳鼻咽喉 | 19713篇 |
儿科学 | 40225篇 |
妇产科学 | 38661篇 |
基础医学 | 187204篇 |
口腔科学 | 39811篇 |
临床医学 | 112618篇 |
内科学 | 262378篇 |
皮肤病学 | 30208篇 |
神经病学 | 106373篇 |
特种医学 | 53665篇 |
外国民族医学 | 435篇 |
外科学 | 208207篇 |
综合类 | 31043篇 |
现状与发展 | 6篇 |
一般理论 | 436篇 |
预防医学 | 92039篇 |
眼科学 | 31357篇 |
药学 | 100054篇 |
4篇 | |
中国医学 | 2987篇 |
肿瘤学 | 75612篇 |
出版年
2018年 | 11739篇 |
2015年 | 11871篇 |
2014年 | 16685篇 |
2013年 | 25240篇 |
2012年 | 32993篇 |
2011年 | 34861篇 |
2010年 | 20728篇 |
2009年 | 20226篇 |
2008年 | 33575篇 |
2007年 | 36678篇 |
2006年 | 37251篇 |
2005年 | 36003篇 |
2004年 | 35083篇 |
2003年 | 34060篇 |
2002年 | 33585篇 |
2001年 | 63615篇 |
2000年 | 65323篇 |
1999年 | 55386篇 |
1998年 | 14651篇 |
1997年 | 13459篇 |
1996年 | 12937篇 |
1995年 | 12221篇 |
1994年 | 11468篇 |
1992年 | 42762篇 |
1991年 | 41280篇 |
1990年 | 40557篇 |
1989年 | 39551篇 |
1988年 | 36963篇 |
1987年 | 36408篇 |
1986年 | 34899篇 |
1985年 | 33102篇 |
1984年 | 24823篇 |
1983年 | 21052篇 |
1982年 | 12666篇 |
1981年 | 11569篇 |
1980年 | 10772篇 |
1979年 | 23923篇 |
1978年 | 17068篇 |
1977年 | 14834篇 |
1976年 | 13386篇 |
1975年 | 15269篇 |
1974年 | 18080篇 |
1973年 | 17560篇 |
1972年 | 16810篇 |
1971年 | 15717篇 |
1970年 | 14914篇 |
1969年 | 14346篇 |
1968年 | 13460篇 |
1967年 | 12017篇 |
1966年 | 11258篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
31.
32.
33.
34.
35.
36.
37.
38.
E. Niclas Jonsson Rujia Xie Scott F. Marshall Rosalin H. Arends 《British journal of clinical pharmacology》2016,81(4):688-699
AimsThe aims were to 1) develop the pharmacokinetics model to describe and predict observed tanezumab concentrations over time, 2) test possible covariate parameter relationships that could influence clearance and distribution and 3) assess the impact of fixed dosing vs. a dosing regimen adjusted by body weight.MethodsIndividual concentration–time data were determined from 1608 patients in four phase 3 studies conducted to assess efficacy and safety of intravenous tanezumab. Patients received two or three intravenous doses (2.5, 5 or 10 mg) every 8 weeks. Blood samples for assessment of tanezumab PK were collected at baseline, 1 h post‐dose and at weeks 4, 8, 16 and 24 (or early termination) in all studies. Blood samples were collected at week 32 in two studies. Plasma samples were analyzed using a sensitive, specific, validated enzyme‐linked immunosorbent assay.ResultsA two compartment model with parallel linear and non‐linear elimination processes adequately described the data. Population estimates for clearance (CL), central volume (V
1), peripheral volume (V
2), inter‐compartmental clearance, maximum elimination capacity (VM) and concentration at half‐maximum elimination capacity were 0.135 l day–1, 2.71 l, 1.98 l, 0.371 l day–1, 8.03 μg day–1 and 27.7 ng ml–1, respectively. Inter‐individual variability (IIV) was included on CL, V
1, V
2 and VM. A mixture model accounted for the distribution of residual error. While gender, dose and creatinine clearance were significant covariates, only body weight as a covariate of CL, V
1 and V
2 significantly reduced IIV.ConclusionsThe small increase in variability associated with fixed dosing is consistent with other monoclonal antibodies and does not change risk : benefit. 相似文献
39.
40.
Wai Man Mandy Chan Yik Weng Yew Thiam Seng Colin Theng Choon Fong Liew Hazel H Oon 《Singapore medical journal》2020,61(4):194
INTRODUCTIONPsoriasis is a chronic inflammatory condition that affects the skin and joints, and is associated with cardiovascular risk factors, including metabolic syndrome (MetS). We aimed to assess the prevalence of MetS in patients with psoriasis and determine whether there was a correlation between psoriasis severity and MetS in a Singapore population.METHODSThis was a cross-sectional study of patients with psoriasis, aged 18–69 years, who attended a tertiary dermatology referral centre in Singapore from October 2007 to February 2009. Fasting glucose, lipids, blood pressure, Psoriasis Area and Severity Index, and body mass index were measured. MetS was diagnosed in the presence of three or more criteria of the modified National Cholesterol Education Program Adult Treatment Panel III.RESULTSAmong 338 patients with psoriasis, there were 238 (70.4%) men and 100 (29.6%) women, who were Chinese (n = 228; 67.5%), Malay (n = 52; 15.4%) and Indian (n = 58; 17.2%). The prevalence of MetS was 45.1%. MetS was 44% more prevalent in patients older than 50 years (p = 0.02). Malay patients with psoriasis were significantly more likely to have hypertriglyceridaemia, elevated fasting plasma glucose and abdominal obesity. There was no significant correlation between psoriasis severity and risk of MetS.CONCLUSIONThe prevalence of MetS in patients with psoriasis in Singapore was 45.1%, or nearly threefold higher than the Singapore general population. Patients with psoriasis should be screened yearly for MetS and any modifiable cardiovascular risk factors should be actively controlled. 相似文献